COVID-19, Pfizer Pill 89% Effective in Preventing Hospitalization and Death

The American laboratory Pfizer assures that its anticovid pill is 89% effective in avoiding hospitalization and death, which provides a light at the end of the tunnel in the face of this pandemic that has claimed the lives of millions of people in the world.

Pfizer announced that a clinical trial on its COVID-19 pill, the first of its kind, showed high effectiveness.

The drug called Paxlovid was able to lower the risk of hospitalization or death by 89% among adult COVID-19 patients at high risk of developing severe forms of the disease, Pfizer said.

The results of this interim clinical trial are so good that the US lab said it will stop recruiting new people for the trial. It added that it will send the data to the Food and Drug Administration (FDA) as soon as possible as part of its “ongoing submission” to obtain authorization for emergency use.

“Today’s news is a real game changer in global efforts to stem the devastation of this pandemic,” said Pfizer CEO Albert Bourla.

“These data suggest that our oral antiviral candidate, if approved or licensed by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of 10 hospitalizations.” added.

The main analysis of the trial evaluated data from 1,219 adults in North and South America, Europe, Africa and Asia.

Several laboratories are working on oral antivirals that would mimic the influenza drug Tamiflu and prevent the disease from progressing to serious stages.

Pfizer began developing its anticovid drug in March 2020, the first specifically designed against coronavirus.